EYPT - EyePoint pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

141.3M

Cash

122.5M

Avg Qtr Burn

-15.42M

Short % of Float

19.29%

Insider Ownership

10.58%

Institutional Own.

86.04%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
YUTIQ Details Chronic non-infectious uveitis	Phase 4 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
DEXYCU Details Post-operative inflammation	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EYP-1901 Details Non-proliferative diabetic retinopathy	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EYP-1901 Details Macular degeneration, Wet age-related macular degeneration Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.